Pricing Log in Create free account

Nektar Therapeutics (NKTR) vs Taysha Gene Therapies, Inc. (TSHA)

Nektar Therapeutics and Taysha Gene Therapies, Inc. are both Biotechnology companies. Nektar Therapeutics and Taysha Gene Therapies, Inc. are of similar size ($1.3B and $1.2B). Taysha Gene Therapies, Inc. grew revenue faster over the last twelve months: 19.0% against −27.2%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −287.8%) and the higher return on invested capital (0.00% vs −40.2%). Across the 16 metrics below, Taysha Gene Therapies, Inc. leads on 9 and Nektar Therapeutics on 7.

Valuation

Metric NKTR TSHA Biotechnology median
P/E n/m n/m 8.50
P/S 21.67 113.26 9.71
P/B 1.31 3.45 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 18.33 78.83 9.21
Earnings yield (18.73%) (11.60%) (33.15%)
Free cash flow yield (19.79%) (10.41%) (25.50%)

Profitability

Metric NKTR TSHA Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (257.80%) 0.00% 0.00%
Net margin (287.84%) 0.00% 0.00%
Free cash flow margin (428.72%) 0.00% 0.00%
Return on equity (35.75%) (47.05%) (56.36%)
Return on assets (24.12%) (37.23%) (48.04%)
Return on invested capital (40.20%) 0.00% 0.00%

Growth

Metric NKTR TSHA Biotechnology median
Revenue growth (TTM) (27.15%) 18.96% 6.02%
EPS growth (last fiscal year) (11.89%) 5.56% 30.26%
Revenue growth, 5-year CAGR (18.43%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NKTR TSHA Biotechnology median
Debt to equity 0.00 0.13 0.00
Current ratio 10.42 17.76 4.72
Net debt to EBITDA 1.77 2.47 0.96

Dividend

Metric NKTR TSHA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric NKTR TSHA Biotechnology median
Market cap 1.29b 1.22b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack